These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38569701)

  • 1. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
    Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
    BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe.
    Zhang J; Kelkar SS; Prabhu VS; Ogando YM; Verma RP; Grall V; Marth C
    Future Oncol; 2024; 20(34):2637-2645. PubMed ID: 39119643
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer that are non-microsatellite instability high (non-MSI-high) or mismatch repair proficient (pMMR) in the United States.
    Kelkar SS; Prabhu VS; Zhang J; Corman S; Macahilig C; Rusibamayila N; Odak S; Duska LR
    Gynecol Oncol Rep; 2022 Aug; 42():101026. PubMed ID: 35800987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
    Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
    Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
    Monk BJ; Smith G; Lima J; Long GH; Alam N; Nakamura H; Meulendijks D; Ghiorghiu D; Banerjee S
    Gynecol Oncol; 2022 Feb; 164(2):325-332. PubMed ID: 34952707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
    Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
    JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
    Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
    Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
    Mevius A; Karl F; Wacker M; Welte R; Krenzer S; Link T; Maywald U; Wilke T
    J Cancer Res Clin Oncol; 2023 May; 149(5):1929-1939. PubMed ID: 35840862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
    Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study.
    Sovak MA; Dupont J; Hensley ML; Ishill N; Gerst S; Abu-Rustum N; Anderson S; Barakat R; Konner J; Poyner E; Sabbatini P; Spriggs DR; Aghajanian C
    Int J Gynecol Cancer; 2007; 17(1):197-203. PubMed ID: 17291253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world treatment patterns and clinical outcomes after introduction of immune checkpoint inhibitors: Results from a retrospective chart review of patients with advanced/metastatic non-small cell lung cancer in the EU5.
    Slowley A; Phiri K; Multani JK; Casey V; Mpima S; Yasuda M; Chen CC; Manuguid F; Chao J; Aziez A; Bell KF; Stojadinovic A
    Thorac Cancer; 2023 Oct; 14(28):2846-2858. PubMed ID: 37592826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
    Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
    Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.
    Bhatia S; Nghiem P; Veeranki SP; Vanegas A; Lachance K; Tachiki L; Chiu K; Boller E; Bharmal M
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer.
    Roncolato F; Lindemann K; Willson ML; Martyn J; Mileshkin L
    Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012160. PubMed ID: 31588998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
    Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
    Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review.
    Bang SM; Kang KW; Song IC; Llamas C; Duan Y; Jeong JY; Lee JH
    J Korean Med Sci; 2023 Nov; 38(44):e345. PubMed ID: 37967874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
    Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
    Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.